Company will use data to direct clinical development of BSI-201 and other drugs.
BiPar Sciences reports that it has demonstrated the overexpression of the PARP (poly-ADP-ribose polymerase) protein in multiple cancers.
The research, presented at the “Conference on Molecular Targets and Cancer Therapeutics” is the first demonstration of PARP overexpression in specific types of cancer, according to the company.
BiPar researchers used the Gene Logic BioExpress® System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue. PARP expression was above the 95% upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer, and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.
“These results allow us to focus our clinical development plan for BSI-201, a PARP inhibitor, by targeting tumor types that have the greatest probability of clinical success,” says BiPar evp, Barry Sherman, M.D.
BSI-201 has been tested as both monotherapy and in combination with standard therapy in Phase I studies in patients with solid tumors.